Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized, placebo-controlled study of oral ALE1 in healthy adults and adults with hypophosphatasia
2025-522378-36-00Phase 2Authorised
- Sponsor
- Alesta Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in hypophosphatasia (HPP) comparing ALE1 with ALE1 matched placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Planned start Jul 2026; status: authorised.
02
Drugs
ALE1
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on 2025-522378-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522378-36-00.